Pilot & Feasibility Program

飞行员

• 批准号: 7925282
• 负责人: JOEL F HABENER
• 金额: $ 43.76万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2015-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7925282
• 关键词: Area; Australia; Award; Benchmarking; Boston; Clinical; Communities; Data; Development; Diabetes Mellitus; Discipline; Eligibility Determination; Endocrinology; Exhibits; Eye; Foundations; Funding; Future; Genomics; Germany; Goals; Grant; Grant Review; Home environment; Immunology; Institution; Instruction; Internet; Investigation; K-Series Research Career Programs; Mails; Measures; Metabolism; Mission; Molecular and Cellular Biology; NIH Program Announcements; Process; Productivity; Publications; Publishing; Recording of previous events; Recruitment Activity; Reporting; Research; Research Institute; Research Personnel; Research Proposals; Research Support; Research Training; Resources; Review Committee; Seeds; Series; Source; Time; Training Programs; Translational Research; United States National Institutes of Health; Work; base; career; clinical care; cohort; density; effectiveness measure; innovation; lectures; member; novel; post-doctoral training; posters; programs; success; symposium; web site

The Pilot and Feasibilty (P&F) grant program aims to provide initial support for meritorious research relevant to diabetes and its complications. Specifically, the program seeks to recruit new investigators and/or new ideas into diabetes research by providing seed funding for innovative lines of investigation so as to enable the awardees to generate substantial preliminary data. It is anticipated that one or two years support at the level of $35,000/year will strongly promote the likelihood of obtaining longer-term support. P&F grant availability and the criteria for eligibility are detailed in the program announcements, which are distributed repeatedly through poster mailings and internet to all area research institutions between December and January. Eligibility criteria, instructions and application materials are featured prominently on the BADERC web site. During the previous five years cycle, 106 completed applications were received; most originated from MGH (38), with significant numbers from BIDMC(17) BWH (15) BMC (18), Joslin (7),Tufts (5) Schepens Eye Research Institute (4) and single applications from others. All grants receive outside review, with two reports received for -70%. The grants and reviews were further evaluated by the BADERC executive committee, who based final funding decisions primarily on reviewer merit scores; when scores are close however, issues of BADERC mission relevance and fair distribution among disciplines and institutions are considered. The distribution of the 19 grants awarded this cycle has favored MGH (10) and BIDMC (5); 45/106 applications focused on metabolism, as did 10/19 P&F grants awarded. Five of 24 Clinical/Translaional applications were funded but none of the immunology proposals, a change from the previous cycle. As to subsequent funding history, of the 29 awardees between 2000-2008 who were considered "new" investigators at the time of their P&F award, 14 have achieved ROI-level funding and 11 achieved ADA/JDRF/foundation awards. This cohort of investigators published of 5-6 publications subsequent to acquiring the P&F award. We consider the P&F grant largely successful in achieving the goals articulated. In the future, the BADERC internal review committee will expand from three to six members to enhance representation.

试点和可行性(P&F)赠款计划旨在为与糖尿病及其并发症相关的有价值的研究提供初步支持。具体地说，该计划寻求在糖尿病研究中招募新的研究人员和/或新的想法，为创新的研究路线提供种子资金，以便使获奖者能够产生大量的初步数据。预计一到两年的35000美元/年的支助将极大地增加获得长期支助的可能性。P&F奖助金的可获得性和资格标准在计划公告中详细说明，这些公告已分发 在12月至1月期间，反复通过海报邮寄和互联网向所有地区的研究机构发送。资格标准、说明和申请材料在BADERC网站的显著位置。在之前的五年周期中，收到了106份完整的申请；大多数申请来自MGH(38份)，其中相当多的申请来自BIDMC(17份)、BWH(15份)、BMC(18份)、Joslin(7份)、Tuft(5份)、Schepens眼科研究所(4份)和其他机构的单一申请。所有赠款都要接受外部审查， 收到两份报告-70%。BADERC执行委员会对赠款和审查进行了进一步的评估，他们主要根据评审员的成绩做出最终的资金决定；然而，当分数接近时，BADERC的使命相关性和学科和机构之间的公平分配问题被考虑在内。本周期授予的19项赠款的分配有利于MGH(10项)和BIDMC(5项)；45/106项申请侧重于新陈代谢，10/19项P&F赠款也是如此。在24个临床/跨国界应用中，有5个获得了资金，但没有一个免疫学提案，与上一个周期有所不同。至于后来的资助历史，在2000-2008年期间被认为是P&F奖时“新”调查人员的29名获奖者中，14人获得了ROI级别的资助，11人获得了ADA/JDRF/基金会奖。这批调查人员在获得P&F奖后发表了5-6份出版物。我们认为，P&F赠款在很大程度上成功地实现了所阐述的目标。未来，BADERC内部审查委员会将从3名成员扩大到6名成员，以增强代表性。